AMP ALS (Accelerating Medicines Partnership)

Our mission is to accelerate therapeutic and biomarker development for ALS. The Accelerating Medicines Partnership (AMP) in Amyotrophic Lateral Sclerosis (AMP ALS) Program brings together the resources and expertise of the NIH and other stakeholders from academia, life science companies, foundations, patient-focused groups, and research nonprofits to tackle the tremendous challenges of diagnosing, understanding, and treating ALS, a progressive and ultimately fatal neurological disease.

More details

In August 2025, AMP ALS launched the ALS Knowledge Portal with more than 10 datasets. As the ALS Knowledge Portal continues to expand, it will become the largest data source for ALS research and expedite the identification of biomarkers and clinical outcome assessments that would allow earlier diagnosis and accelerated drug development.

AMP ALS is a component of the public-private partnership called for in H.R.3537-Accelerating Access to Critical Therapies for ALS Act (ACT for ALS), signed into law by President Biden in December 2021. Multiple clinical sites across the country have joined the NIH-funded Access for All in ALS (ALL ALS) Consortium, which will recruit people with ALS and those at risk for the disease to collect clinical data and biosamples.

Personal impact

We have not directly used this resource.

Related information

Any other content I created about this resource is listed here.